To explore whether the decrease of released IL1B in CD44s deficient cells was responsible for damaged tumor proliferation and invasion, Bel7402 siCD44 and Huh7 siCD44 cells were treated with human recombinant IL1B for 24 h. Here, IL1B is linked to neoplasm.